Symptom Management and Supportive Care of the Patient With Brain Metastases

  • Herbert B. Newton
Part of the Cancer Treatment and Research book series (CTAR, volume 136)


The focus of care for patients with brain metastases will always be on therapeutic options such as surgery, radiotherapy, and chemotherapy. However, proper symptom management and supportive care of non-therapeutic issues will be equally as important, including treatment of seizures, use of anticonvulsants, corticosteroids, and gastric acid inhibitors, assessment of swallowing dysfunction, treatment of thromboembolic events, appropriate use and safe application of anticoagulation, and evaluation of psychiatric issues. Appropriate management of these supportive aspects of patient care will improve overall quality of life and allow the patient and family to more easily concentrate on treatment.


Brain Tumor Suicidal Ideation Seizure Activity Symptom Management Pneumocystis Carinii Pneumonia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ruhstaller T, Roe H, Thurlimann B, Nicoll JJ. The multidisciplinary meeting: An indispensable aid to communication between different specialties. Eur J Cancer [2006; Epub ahead of print].Google Scholar
  2. 2.
    Ptacek JT, Ptacek JJ. Patients’ perceptions of receiving bad news about cancer. J Clin Oncol 2001; 19:4160–4164.PubMedGoogle Scholar
  3. 3.
    Back AL, Arnold RM. Discussing prognosis: ‘How much do you want to know?’ Talking to patients who are prepared for explicit information. J Clin Oncol 2006; 24:4209–4213.CrossRefPubMedGoogle Scholar
  4. 4.
    Back AL, Arnold RM. Discussing prognosis: ‘How much do you want to know?’ Talking to patients who do not want information or who are ambivalent. J Clin Oncol 2006; 24:4214–4217.CrossRefPubMedGoogle Scholar
  5. 5.
    Feldman GB. The role of support in treating the brain tumor patient. In: Cancer of the Nervous System. Black PM, Loeffler JS (Eds.). Blackwell Science, Cambridge 1997; 17:335–345.Google Scholar
  6. 6.
    Given BA, Given CW, Kozachik S. Family support in advanced cancer. CA Cancer J Clin 2001; 51:213–231.CrossRefPubMedGoogle Scholar
  7. 7.
    Nijboer C, Tempelaar R, Triemstra M, van den Bos GAM, Sanderman R. The role of social and psychologic resources in caregiving of cancer patients. Cancer 2001; 91:1029–103CrossRefPubMedGoogle Scholar
  8. 8.
    Glantz M, Recht LD. Epilepsy in the cancer patient. In: Handbook of Clinical Neurology, Vol. 25 (69): Neuro-Oncology, Part III. Vecht CJ (Ed.). Elsevier Science, Amsterdam 1997; 2:9–18.Google Scholar
  9. 9.
    Newton HB. Neurological complications of systemic cancer. Amer Fam Phys 1999; 59:878–886.Google Scholar
  10. 10.
    Schaller B, Rüegg SJ. Brain tumor and seizures: Pathophysiology and its implications for treatment revisited. Epilepsia 2003; 44:1223–1232.CrossRefPubMedGoogle Scholar
  11. 11.
    Ettinger AB. Structural causes of epilepsy: Tumors, cysts, stroke, and vascular malformation. Neurol Clin 1994; 12:41–56.PubMedGoogle Scholar
  12. 12.
    Highland MM, Berger MS, Kunkel DD, Franck JE, Ghatan S, Ojemannn GA. Changes in gamma-aminobutyric acid and somatostatin in epileptic cortex associated with low-grade gliomas. J Neurosurg 1992; 77:209–216.CrossRefGoogle Scholar
  13. 13.
    Bateman DE, Hardy JA, McDermott JR, Parker DS, Edwardson JA. Amino acid neurotransmitter levels in gliomas and their relationship to the incidence of epilepsy. Neurol Res 1988; 10:112–114.PubMedGoogle Scholar
  14. 14.
    Ye ZC, Sontheimer H. Glioma cells release excitotoxic concentrations of glutamate. Cancer Res 1999; 59:4383–4391.PubMedGoogle Scholar
  15. 15.
    Behrens PF, Langemann H, Strohschein R, Draeger J, Hennig J. Extracellular glutamate and other metabolites in and around RG2 rat glioma: an intracerebral microdialysis study. J Neuro-Oncol 2000; 47:11–22.CrossRefGoogle Scholar
  16. 16.
    Brodie MJ, Dichter MA. Antiepileptic drugs. New Engl J Med 1996; 334: 168–175.CrossRefPubMedGoogle Scholar
  17. 17.
    Britton JW, So EL. Selection of antiepileptic drugs: A practical approach. Mayo Clin Proc 1996; 71:778–786.CrossRefPubMedGoogle Scholar
  18. 18.
    Mattson RH, Cramer BS, Collins JF, and the Department of Veterans Affairs Epilepsy Cooperative Study Group. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. New Engl J Med 1992; 327:765–771.PubMedCrossRefGoogle Scholar
  19. 19.
    Dichter MA, Brodie MJ. New antiepileptic drugs. New Eng J Med 1996; 334:1583–1590.CrossRefPubMedGoogle Scholar
  20. 20.
    Rosenfeld WE. Topiramate: A review of preclinical, pharmacokinetic, and clinical data. Clin Therap 1997; 19:1294-CrossRefGoogle Scholar
  21. 21.
    Newton HB, Goldlust S, Pearl D. Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neuro-Oncol 2006; 78:99–102.CrossRefGoogle Scholar
  22. 22.
    Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003; 2:404–409.CrossRefPubMedGoogle Scholar
  23. 23.
    North JB, Penhall RK, Hanieh A, Frewin DB, Taylor WB. Phenytoin and postoperative epilepsy. A double-blind study. J Neurosurg 1983; 58:672–677.CrossRefPubMedGoogle Scholar
  24. 24.
    Boarini DJ, Beck DW, VanGilder JC. Postoperative prophylactic anticonvulsant therapy in cerebral gliomas. Neurosurg 1985; 16:290–292.CrossRefGoogle Scholar
  25. 25.
    Cohen N, Strauss G, Lew R, Silver D, Recht L. Should prophylactic anticonvulsants be administered to patients with newly-diagnosed cerebral metastases? A retrospective analysis. J Clin Oncol 1988; 6:1621–1624.PubMedGoogle Scholar
  26. 26.
    Franceschetti S, Binelli S, Casazza M, et al. Influence of surgery and antiepileptic drugs on seizures symptomatic of cerebral tumours. Acta Neurochir 1990; 103:47–51.CrossRefGoogle Scholar
  27. 27.
    Shaw MDM. Post-operative epilepsy and the efficacy of anticonvulsant therapy. Acta Neurochir Suppl 1990; 50:55–57.Google Scholar
  28. 28.
    Foy PM, Chadwick DW, Rajgopalan N, Johnson AL, Shaw MDM. Do prophylactic anticonvulsant drugs alter the pattern of seizures after craniotomy? J Neurol Neurosurg Psych 1992; 55:753–757.CrossRefGoogle Scholar
  29. 29.
    Glantz MJ, Cole BF, Friedberg MH, et al. A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurol 1996; 46:985–991.Google Scholar
  30. 30.
    Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurol 2000; 54:1886–1893.Google Scholar
  31. 31.
    Newton HB, Turowski RC, Stroup TJ, McCoy LK. Clinical presentation, diagnosis, and pharmacotherapy of patients with primary brain tumors. Ann Pharmacother 1999; 33:816–832.CrossRefPubMedGoogle Scholar
  32. 32.
    Ohnishi T, Sher PB, Posner JB, Shapiro WB. Capillary permeability factor secreted by malignant brain tumor. Role in peritumoral edema and possible mechanism for anti-edema effect of glucocorticoids. J Neurosurg 1990; 72: 245–251.CrossRefPubMedGoogle Scholar
  33. 33.
    Del Maestro RF, Megyesi JF, Farrell CL. Mechanisms of tumor-associated edema: A review. Can J Neurol Sci 1990; 17:177–183.PubMedGoogle Scholar
  34. 34.
    Samdani AF, Tamargo RJ, Long DM. Brain tumor edema and the role of the blood-brain barrier, in Vecht CJ (ed.): Handbook of Clinical Neurology, Vol. 23 (67): Neuro-Oncology, Part I. Amsterdam, Elsevier Science, 1997; 4:71–102.Google Scholar
  35. 35.
    Mukwaya G. Immunosuppressive effects and infections associated with corticosteroid therapy. Pediatr Infect Dis J 1988; 7:499–504.CrossRefPubMedGoogle Scholar
  36. 36.
    Østergaard L, Hochberg FH, Rabinov JD, et al. Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors. J Neurosurg 1999; 90:300–305.CrossRefPubMedGoogle Scholar
  37. 37.
    Lester RS, Knowles SR, Shear NH. The risks of systemic corticosteroid use. Dermatol Clin 1998; 16:277–286.PubMedGoogle Scholar
  38. 38.
    Weissman DE, Dufer D, Vogel V, Abeloff DD. Corticosteroid toxicity in neuro-oncology patients. J Neuro-Oncol 1987; 5:125–128.CrossRefGoogle Scholar
  39. 39.
    Fadul CE, Lemann W, Thaler HT, Posner JB. Perforation of the gastrointestinal tract in patients receiving steroids for neurologic disease. Neurol 1988; 38: 348–352.Google Scholar
  40. 40.
    Stiefel FC, Breitbart WS, Holland JC. Corticosteroids in cancer: Neuropsychiatric complications. Cancer Investig 1989; 7:479–491.CrossRefGoogle Scholar
  41. 41.
    Dropcho EJ, Soong SJ. Steroid-induced weakness in patients with primary brain tumors. Neurol 1991; 41:1235–1239.Google Scholar
  42. 42.
    Batchelor TT, Taylor LT, Thaler HT, Posner JB, DeAngelis LM. Steroid myopathy in cancer patients. Neurol 1997; 48:1234–1238.Google Scholar
  43. 43.
    Joseph JC. Corticosteroid-induced osteoporosis. Am J Hosp Pharm 1994; 51:188–197.PubMedGoogle Scholar
  44. 44.
    McIlwain HH. Glucocorticoid-induced osteoporosis: pathogenesis, diagnosis, and management. Preventive Med 2003; 36:243–249.CrossRefGoogle Scholar
  45. 45.
    Mahindra AK, Grossman SA. Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors. J Neuro-Oncol 2003; 63:263–270.CrossRefGoogle Scholar
  46. 46.
    Mathew BS, Grossman SA. Pneumocystic carinii pneumonia prophylaxis in HIV negative patients with primary CNS lymphoma. Cancer Treat Rev 2003; 29:105–119.CrossRefPubMedGoogle Scholar
  47. 47.
    Ellershaw JE, Kelly MJ. Corticosteroids and peptic ulceration. Palliative Med 1994; 8:313–319.CrossRefGoogle Scholar
  48. 48.
    Garnett WR, Garabedian-Ruffalo SM. Identification, diagnosis, and treatment of acid-related diseases in the elderly: Implications for long-term care. Pharmacother 1997; 17:938–958.Google Scholar
  49. 49.
    Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacother 1997; 17:22–37.Google Scholar
  50. 50.
    Lee AYY, Levine MN. Management of venous thromboembolism in cancer patients. Oncol 2000; 14:409–421.Google Scholar
  51. 51.
    Gomes MPV, Deitcher SR. Diagnosis of venous thromboembolic disease in cancer patients. Oncol 2003; 17:126–139.Google Scholar
  52. 52.
    Sawaya R, Zuccarello M, Elkalliny M, Nighiyama H. Postoperative venous thromboembolism and brain tumors: part I. Clinical profile. J Neuro-Oncol 1992; 14:119–125.Google Scholar
  53. 53.
    Hamilton MG, Hull RD, Pineo GF. Venous thromboembolism in neurosurgery and neurology patients: A review. Neurosurg 1994; 34:280–296.CrossRefGoogle Scholar
  54. 54.
    Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma. An evidence-based review. Cancer 2000; 89:640–646.CrossRefPubMedGoogle Scholar
  55. 55.
    Brandes AA, Scelzi E, Salmistraro E, et al. Incidence and risk of thromboembolism during treatment of high-grade gliomas: a prospective study. Eur J Cancer 1997; 33:1592–1596.CrossRefPubMedGoogle Scholar
  56. 56.
    Quevedo JF, Buckner JC, Schmidt JL, Dinapoli RP, O’Fallon JR. Thromboembolism in patients with high-grade glioma. Mayo Clin Proc 1994; 69:329–332.PubMedGoogle Scholar
  57. 57.
    Ruff RL, Posner JB. The incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol 1983; 13:334–336.CrossRefPubMedGoogle Scholar
  58. 58.
    Altshuler E, Moosa H, Selker RG, Vertosick FT. The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary brain tumors. Neurosurg 1990; 27:74–77.CrossRefGoogle Scholar
  59. 59.
    Levin JM, Schiff D, Loeffler JS, Fine HA, Black PML, Wen PY. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurol 1993; 43:1111–1114.Google Scholar
  60. 60.
    Schiff D, DeAngelis LM. Therapy of venous thromboembolism in patients with brain metastases. Cancer 1994; 73:493–498.CrossRefPubMedGoogle Scholar
  61. 61.
    Weitz JI. Low-molecular-weight heparins. New Engl J Med 1997; 337: 688–698.CrossRefPubMedGoogle Scholar
  62. 62.
    Dorfman GS. Evaluating the roles and functions of vena caval filters: will data be available before or after these devices are removed from the market? Radiol 1992; 185:15–17.Google Scholar
  63. 63.
    Buchholz D. Neurologic causes of dysphagia. Dysphagia 1987; 1:152–156.CrossRefGoogle Scholar
  64. 64.
    Kirshner HS. Causes of Neurogenic dysphagia. Dysphagia 1989; 3:184–188.CrossRefPubMedGoogle Scholar
  65. 65.
    Barer DH. The natural history and functional consequences of dysphagia after hemispheric stroke. J Neurol Neurosurg Psychiatry 1989; 52:236–241.CrossRefPubMedGoogle Scholar
  66. 66.
    Lieberman AN, Horowitz L, Redmond P, Pachter L, Lieberman I, Leibowitz M. Dysphagia in Parkinson’s disease. Am J Gastroenterol 1980; 74:157–160.PubMedGoogle Scholar
  67. 67.
    Daly DD, Code CF, Anderson HA. Disturbances of swallowing and esophageal motility in patients with multiple sclerosis. Neurol 1962; 59:250–256.Google Scholar
  68. 68.
    Robbins J. Swallowing in ALS and motor neuron disease. Neurol Clin 1987; 5:213–229PubMedGoogle Scholar
  69. 69.
    Buchholz D. Neurologic evaluation of dysphagia. Dysphagia 1987; 1:187–192.CrossRefGoogle Scholar
  70. 70.
    Frank Y, Schwartz SB, Epstein NE, Beresford HR. Chronic dysphagia, vomiting and gastroesophageal reflux as manifestations of a brain stem glioma: A case report. Pediatr Neurosci 1989; 15:265–268.CrossRefPubMedGoogle Scholar
  71. 71.
    Straube A, Witt TN. Oculo-bulbar myasthenic symptoms as the sole sign of tumour involving or compressing the brain stem. J Neurol 1990; 237:369–371.CrossRefPubMedGoogle Scholar
  72. 72.
    Cunningham ET, Donner MW, Jones B, Point SM. Anatomical and physiological overview, in Jones B, Donner MW (Eds.): Normal and Abnormal Swallowing. Imaging in Diagnosis and Therapy. Springer-Verlag, New York, 1991; 2:7–32.Google Scholar
  73. 73.
    Dodds WJ, Stewart ET, Logemann JA. Physiology and radiology of the normal oral and pharyngeal phases of swallowing. Am J Roentgenol 1989; 154: 953–963.Google Scholar
  74. 74.
    Sessle BJ, Henry JL. Neural mechanisms of swallowing: Neurophysiological and neurochemical studies on brain stem neurons in the solitary tract region. Dysphagia 1989; 4:61–75.CrossRefPubMedGoogle Scholar
  75. 75.
    Meadows JC. Dysphagia in unilateral cerebral lesions. J Neurol Neurosurg Psych 1973; 36:853–860.CrossRefGoogle Scholar
  76. 76.
    Newton HB, Newton C, Pearl D, Davidson T. Swallowing assessment in primary brain tumor patients with dysphagia. Neurol 1994; 44:1927–1932.Google Scholar
  77. 77.
    Emick-Herring B, Wood P. A team approach to neurologically based swallowing disorders. Rehabil Nurs 1990; 15:126–132.PubMedGoogle Scholar
  78. 78.
    Dodds WJ, Logemann JA, Stewart ET. Radiologic assessment of abnormal oral and pharyngeal phases of swallowing. Am J Roentgenol 1990; 154:965–974.Google Scholar
  79. 79.
    Bloch AS. Nutritional management of patients with dysphagia. Oncol 1993; 7:127–137.Google Scholar
  80. 80.
    Levine SH, Jones LD, Sack DA. Evaluation and treatment of depression, anxiety, and insomnia in patients with cancer. Oncol 1993; 7:119–125.Google Scholar
  81. 81.
    Breitbart W. Psycho-Oncology: Depression, anxiety, delirium. Sem Oncol 1994; 21:754–769.Google Scholar
  82. 82.
    Pirl WF, Roth AJ. Diagnosis and treatment of depression in cancer patients. Oncol 1999; 13:1293–1301.Google Scholar
  83. 83.
    Stark D, Kiely M, Smith A, Vilikova G, House A, Selby P. Anxiety disorders in cancer patients: Their nature, associations, and relation to quality of life. J Clin Oncol 2002; 20:3137–3148.CrossRefPubMedGoogle Scholar
  84. 84.
    Schwartz L, Lander M, Chochinov HM. Current management of depression in cancer patients. Oncol 2002; 16:1102–1110.Google Scholar
  85. 85.
    Maguire P. Improving the recognition of concerns and affective disorders in cancer patients. Ann Oncol 2002; 13:177–181.CrossRefPubMedGoogle Scholar
  86. 86.
    American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC. American Psychiatric Association, 1994; 317–391.Google Scholar
  87. 87.
    Bukberg J, Penman D, Holland JC. Depression in hospitalized cancer patients. Psychosomatics 1984; 46:199–212.Google Scholar
  88. 88.
    Redd WH, Montgomery GH, DuHamel KN. Behavioral intervention for cancer treatment side effects. J Natl Cancer Inst 2001; 93:810–823.CrossRefPubMedGoogle Scholar
  89. 89.
    Newell SA, Sanson-Fisher RW, Savolainen NJ. Systematic review of psychological therapies for cancer patients: Overview and recommendations for future research. J Natl Cancer Inst 2002; 94:558–584.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Herbert B. Newton
    • 1
  1. 1.Dardinger Neuro-Oncology Center Department of NeurologyThe Ohio State University HospitalsColumbusUSA

Personalised recommendations